Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

PNC-27: does it work, is it legal, and what does it cost?

A lab-stage anticancer peptide tested only in lab-dish cells and mice; no human trials; FDA has warned patients not to use PNC-27 products sold online.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about PNC-27
Does it work in people?Evidence: Animal-only evidence

No randomized human trial of this peptide; the grade rests on animal and lab studies. See the evidence

Is it legal?Regulatory: Unscheduled

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [9] [10] See legal status

What does it cost?Not available through licensed channels.
Side effects?No human safety data of any kind. Contamination risk: FDA found the bacterium Variovorax paradoxus in a PNC-27 inhalation solution sold online. Theoretical risk of pore formation in any cell expressing membrane HDM-2, immune reactions to a foreign peptide, and infusion reactions. See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is PNC-27?

PNC-27 is a designed peptide that links a fragment of the p53 protein (a natural tumor suppressor) to a sequence that carries it into cells; in lab dishes it forms pores in the membranes of cancer cells that display the protein HDM-2 and kills them while sparing normal cells. All evidence is from cell lines and a small number of mouse xenograft experiments (human tumors grown in mice), and no human trial has ever been registered or published. It is not FDA approved and never has been reviewed; in January 2017 FDA warned cancer patients not to use PNC-27 products sold online after finding bacterial contamination in a sample.

PNC-27 is a synthetic 32 amino acid peptide: residues 12 to 26 of the p53 HDM-2 binding domain fused to the penetratin membrane transit sequence. It is also known as PNC 27, p53 HDM-2 binding peptide, PNC-27 anticancer peptide.

How does it work?

The p53 derived segment of PNC-27 binds HDM-2 (MDM2), which is expressed on the plasma membrane of many cancer cells but not on normal cells. On binding, the peptide oligomerizes and forms transmembrane pores, causing rapid necrotic cell death within hours (the authors call this poptosis). Later work suggests PNC-27 also disrupts mitochondrial membranes in cancer cells. Cells lacking membrane HDM-2 are not affected in these assays.

Key facts
ClusterImmune and antimicrobial
RoutesIn vitro exposure only (published studies); Nebulized solution, intravenous solution, vaginal or rectal suppository (as sold online, untested)
Conditions studiedAdvanced prostate cancer
Recordv2, reviewed, verified Sep 29, 2026

What does the evidence say about PNC-27?

Evidence: Animal-only evidenceGrade assigned per the methodology.

In vitro work from one research group shows PNC-27 kills a range of cancer cell lines (pancreatic, breast, leukemia, cervical, and others) by membrane pore formation, with no effect on untransformed cells at the same concentrations. Mouse xenograft experiments with the related PNC-28 peptide showed tumor shrinkage. No human trial, dose finding study, or pharmacokinetic study has been published, so the evidence is graded animal-only and human efficacy and safety are unknown.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials0n/a
Human observational studies0n/a
Animal studies3n/a
All indexed studies3n/a

Human evidence

No indexed human trial identified. No clinical trial of PNC-27 appears in the published literature, and FDA has stated it has not evaluated or approved PNC-27 for any disease. Products sold online as nebulized solutions, intravenous solutions, or suppositories have never been tested in people.

Animal evidence

Mouse xenograft studies with the sister peptide PNC-28 reported necrosis and shrinkage of human pancreatic cancer implants. PNC-27 itself has been characterized mostly in cell culture: it kills HDM-2 positive cancer cell lines within hours by pore formation and has no cytotoxicity toward normal fibroblasts, keratinocytes, or hematopoietic cells in the same assays. Toxicology, pharmacokinetics, and immunogenicity in animals have not been reported.

Key studies

Indexed studies of PNC-27
StudyDesign and populationOutcomeGrade
Anti-cancer peptide PNC-27 kills cancer cells by unique interactions with plasma membrane-bound hdm-2 and with mitochondrial membranes causing mitochondrial disruption2024 PMID 38802154In vitro cell culture studyHuman cancer cell lines and untransformed control cellsPNC-27 induced pore formation and mitochondrial disruption in cancer cells expressing membrane HDM-2 with no effect on normal cellsEvidence: Animal-only evidence
Poptosis or peptide-induced transmembrane pore formation: a novel way to kill cancer cells without affecting normal cells2024 PMID 38927351Narrative review by the originating laboratoryCell line and mouse xenograft data on PNC-27 and PNC-28Summarizes the membrane HDM-2 targeting mechanism and preclinical selectivity; no human dataEvidence: Animal-only evidence
The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells2008 PMID 18931881In vitro and mouse xenograft studyHuman pancreatic cancer cell lines and nude mice bearing xenograftsThe related peptide PNC-28 caused tumor cell necrosis in culture and tumor shrinkage in miceEvidence: Animal-only evidence

Conditions studied

Conditions with evidence for PNC-27
ConditionGradeNote
Advanced prostate cancerEvidence: Animal-only evidenceKilled cancer cells in lab and mouse studies; no human trial; FDA warned cancer patients in 2017 not to use PNC-27 products.

Is PNC-27 legal in the United States?

Regulatory: UnscheduledWADA: WADA prohibited

FDA and compounding status

PNC-27 is not an FDA approved drug and is not part of any approved drug. As of the last verification date it does not appear in any FDA 503A category or on the list of withdrawn nominations, and it is not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it from bulk. FDA has described PNC-27 as an unapproved drug product promoted as a treatment or cure for cancer, and in January 2017 an FDA laboratory found bacterial contamination in a PNC-27 sample.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

No regulatory events recorded.

Full tracker for PNC-27 or the category-wide tracker.

Email me when PNC-27's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of PNC-27 used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Not established in human literature. Cell culture studies used micromolar concentrations in vitro; no animal or human dose can be derived from them.

Routes reported

Routes of administration reported for PNC-27
#Route
1In vitro exposure only (published studies)
2Nebulized solution, intravenous solution, vaginal or rectal suppository (as sold online, untested)

What are the side effects and interactions of PNC-27?

Side effects

Side effects reported for PNC-27
#Reported side effect
1No human safety data of any kind
2Contamination risk: FDA found the bacterium Variovorax paradoxus in a PNC-27 inhalation solution sold online
3Theoretical risk of pore formation in any cell expressing membrane HDM-2, immune reactions to a foreign peptide, and infusion reactions
4Delay of proven cancer treatment while using it

Interactions

Interactions reported for PNC-27
#Interaction
1No interaction studies exist
2Unknown effect on concurrent chemotherapy, immunotherapy, or radiation

Contraindications

Contraindications for PNC-27
#Contraindication
1Any use outside a registered clinical trial (none exists)
2Pregnancy and breastfeeding (no data)
3Immunocompromised patients face the highest risk from contaminated products

How do people access PNC-27 legally?

Typical cost: Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Not available

    Not legally available for human use in the United States.

  • Not available

    No registered clinical trial is recruiting as of the last verified date.

  • Not available

    Products sold online are unapproved and FDA has specifically warned against them.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. PeptideAgent has not found an FDA warning letter or review that names PNC-27. [6] [7] [8]

Being offered does not change the legal status of PNC-27. PNC-27 is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [9] [10]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [6] [10] [11] [12] [13] [14]

What that means for you

  • A pharmacy that compounds PNC-27 is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [6] [11]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [14]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [15]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [16] [17]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [10]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, PNC-27 is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [5]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound PNC-27, with or without a prescription. [9]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [18] [19] [20]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [8] [20] [21]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [14] [22] [23] [24] [25] [26]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [14]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [18]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [8]
  • Pharmacy: Is this made for me on a prescription written in my name? [21]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [8] [20]
  • Prescriber: What is the legal basis for a pharmacy to compound PNC-27? Is it FDA approved or on the 503A bulks list? [9] [14]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [8]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [15]

Frequently asked questions

Is PNC-27 legal or FDA approved?

No. PNC-27 has never been reviewed or approved by FDA and is not on any compounding list (FDA's lists of ingredients pharmacies may use), so no licensed pharmacy can make it. In January 2017 FDA warned cancer patients not to purchase or use PNC-27 products sold online after an FDA laboratory found the bacterium Variovorax paradoxus in a sample marketed for inhalation. [4]

Does PNC-27 cure cancer?

There is no evidence in people. PNC-27 kills cancer cell lines in a dish by punching holes in cells that display HDM-2 on their surface, and a related peptide shrank pancreatic tumors in mice. No human trial has ever been published. Cell culture results routinely fail to translate to patients, and using an untested product instead of proven treatment can be harmful. [1] [3] [4]

How does PNC-27 work?

It fuses a piece of the p53 protein, which binds HDM-2, to a cell penetrating sequence. Many cancer cells carry HDM-2 in their outer membrane; PNC-27 binds it, clusters, and forms pores that cause the cell to die by necrosis within hours. Normal cells without membrane HDM-2 are unaffected in the assays. This mechanism has been shown only in cell culture. [1] [2]

What are the side effects of PNC-27?

Unknown, because it has never been given to people in a study. The documented harm so far is contamination: FDA found live bacteria in a PNC-27 solution sold online, which could cause serious infection in people with cancer or weakened immunity. Theoretical risks include damage to any normal tissue expressing membrane HDM-2 and immune reactions. [2] [4]

How is PNC-27 taken?

It is not. Published work is confined to cell culture and mice. Online sellers offer nebulizer solutions, intravenous solutions, and suppositories, none of which have been studied for absorption, dose, or safety in humans. [4]

How much does PNC-27 cost?

It is not available through any licensed channel, so there is no legitimate price. Unregulated sellers have charged thousands of dollars per course for unapproved, untested product. Any money spent is at risk with no evidence of benefit. [4]

Is PNC-27 banned by WADA?

Yes, by default. PNC-27 has no approval from any government health authority for human use, so it falls under section S0 of the WADA Prohibited List and is prohibited at all times. It has no performance rationale in any case. [5]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Krzesaj P et al. Anti-cancer peptide PNC-27 kills cancer cells by unique interactions with plasma membrane-bound hdm-2 and with mitochondrial membranes. Ann Clin Lab Sci 2024PubMed 38802154, 2024
  2. [2]Pincus MR et al. Poptosis or peptide-induced transmembrane pore formation: a novel way to kill cancer cells without affecting normal cells. Biomedicines 2024PubMed 38927351, 2024
  3. [3]Bowne WB et al. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol 2008PubMed 18931881, 2008
  4. [4]FDA warns cancer patients not to use PNC-27 products for treatment (January 2017) (Wayback Machine capture of the FDA page, March 7, 2026)FDA, 2017
  5. [5]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  6. [6]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
  7. [7]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
  8. [8]FDA to telehealth companies: What to know when promoting compounded drugsFDA, 2026
  9. [9]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA
  10. [10]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2)FDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 29). PNC-27: evidence, legality, and access. https://peptideagent.ai/peptides/pnc-27
HTML link
<a href="https://peptideagent.ai/peptides/pnc-27">PNC-27: evidence, legality, and access</a>, PeptideAgent, updated September 29, 2026.